ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
17 hedge funds and large institutions have $293K invested in ImmunoCellular Therapeutics, Ltd. in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 5 closing their positions.
6% less funds holding
Funds holding: 18 → 17 (-1)
16% less capital invested
Capital invested by funds: $348K → $293K (-$55K)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$55.2K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$8.51K |
| 3 |
Goldman Sachs
New York
|
+$8.23K |
| 4 |
TCM
Tradewinds Capital Management
Bellingham,
Washington
|
+$68 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$30.6K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$23K |
| 3 |
Bank of New York Mellon
New York
|
-$10K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$7.66K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$5K |
IMUC Hedge Fund Activity: Q4 2017 in Review
17 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q4 2017, worth a combined $293K — down 16% from $348K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IMUC and 4 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 2 added.
The largest buyer was Virtu Financial, adding an estimated $55.2K. The largest seller was Renaissance Technologies, cutting an estimated $30.6K.
- 17 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q4 2017, down from 18 in Q3 2017.
- Funds reported $293K of ImmunoCellular Therapeutics, Ltd. stock for Q4 2017, down 16% quarter-over-quarter.
- 4 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q4 2017 and 5 closed out, a net change of -1 holder.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q4 2017 was Virtu Financial, an estimated $55.2K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q4 2017 was Renaissance Technologies, an estimated $30.6K sold.
Based on aggregated 13F filings for Q4 2017.